Does Pennsylvania Medicaid cover Wegovy, Ozempic & Zepbound? (2026)
✓ Verified against PA DHS Medical Assistance bulletin
By Hemant Adhikari, founder of WillItCover · Digested from the PA DHS Medical Assistance bulletin (Nov 24, 2025) · Last verified July 7, 2026
Short answer: weight-loss coverage ended for adults on January 1, 2026. Pennsylvania Medicaid no longer covers GLP-1s for weight loss for adults 21 and older. It still covers them for type 2 diabetes, for members under 21, and for specific non–weight-loss conditions (sleep apnea, heart disease, MASH). Anyone continuing past December 31, 2025 needed a new authorization.
What changed on January 1, 2026
Under a Pennsylvania Department of Human Services Medical Assistance bulletin issued November 24, 2025, Medicaid stopped covering GLP-1s (Wegovy, Zepbound, Saxenda and the diabetes brands used off-label) for weight loss in adults 21 and older, effective January 1, 2026.
Who and what is still covered
- Members under 21 — still covered for weight/obesity with prior authorization.
- Type 2 diabetes — covered (Ozempic, Mounjaro, Trulicity, Victoza) with prior authorization.
- Obstructive sleep apnea (Zepbound), cardiovascular risk (Wegovy) and MASH liver disease — covered under those FDA indications with prior authorization.
If you were cut — what you can do
- Appeal within 15 days. If you got a denial letter and file an appeal within 15 days of the date on the letter, your GLP-1 coverage should continue during the appeal.
- Ask your prescriber to re-authorize under a covered indication if you have diabetes, sleep apnea, established heart disease, or MASH.
- Weight-loss surgery may be covered — a separate Medicaid benefit with its own criteria.
- If you also have Medicare (dual-eligible), the Medicare GLP-1 Bridge ($50/month, July 2026–Dec 2027) may be an option. See how the Bridge works →
Not sure where you stand? Check in two minutes
Tell us your plan, drug and reason, and see whether you're likely covered — plus exactly what to document or how to appeal.
Check my coverage
Frequently asked questions
Does Pennsylvania Medicaid cover Wegovy for weight loss?
Not for adults 21 and older, as of January 1, 2026. Pennsylvania Medicaid ended weight-loss GLP-1 coverage for adults. Members under 21 can still be covered for weight/obesity with prior authorization.
Does Pennsylvania Medicaid still cover Ozempic for diabetes?
Yes. GLP-1s such as Ozempic, Mounjaro, Trulicity and Victoza remain covered for type 2 diabetes with prior authorization.
Can I appeal the loss of my GLP-1 coverage?
Yes. If you received a denial letter and file an appeal within 15 days of the date on the letter, your GLP-1 coverage should continue during the appeal process.
Are there any weight-related exceptions?
Coverage continues under non–weight-loss indications: Zepbound for obstructive sleep apnea, Wegovy for cardiovascular risk reduction with established heart disease, and Wegovy for MASH liver disease — each with prior authorization.
How we know this: this page is based on the Pennsylvania DHS Medical Assistance bulletin issued November 24, 2025 (effective January 1, 2026) and Pennsylvania Health Law Project guidance, which ended adult weight-loss GLP-1 coverage while keeping under-21, diabetes and other-indication coverage. Medicaid drug rules change frequently and managed-care plans vary — we re-verify this page against the source and date it. Last verified July 7, 2026. This is general information, not medical or coverage advice, and not a guarantee — your specific plan controls.
Related: Weight-loss coverage — the full guide · Does Medicare cover Wegovy? · California (Medi-Cal) · Texas · Florida · New York · Illinois